Transitional Cell Carcinoma Completed Phase 2 Trials for Paclitaxel (DB01229)

Also known as: Carcinoma, Transitional Cell / Carcinoma transitional cell / Transitional cell carcinoma (morphologic abnormality)

IndicationStatusPhase
DBCOND0031000 (Transitional Cell Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT03051373Phase 2 Trial of Nab-paclitaxel Plus S-1 vs Gemcitabine Plus Cisplatin as 1-line Chemotherapy of Patients With Local Advanced and/or Metastatic Transitional Cell Carcinoma of Urothelial TractTreatment
NCT02581982Paclitaxel and Pembrolizumab in Treating Patients With Refractory Metastatic Urothelial CancerTreatment
NCT02109328Alisertib in Chemotherapy-pretreated Urothelial CancerTreatment
NCT00683059Single Agent Abraxane as Second Line Therapy in Bladder CancerTreatment
NCT00154687Weekly TP-HDFL in the Treatment of Advanced TCCTreatment